HC Wainwright Reiterates “Buy” Rating for Kamada (NASDAQ:KMDA)

Kamada (NASDAQ:KMDA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $11.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 54.93% from the company’s current price.

Kamada Stock Performance

Kamada stock opened at $7.10 on Thursday. The firm has a market cap of $408.11 million, a price-to-earnings ratio of 25.36, a PEG ratio of 0.97 and a beta of 0.99. Kamada has a 52-week low of $4.74 and a 52-week high of $9.15. The firm has a 50 day moving average price of $7.06 and a two-hundred day moving average price of $6.13.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares in the last quarter. Aristides Capital LLC lifted its stake in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 6,850 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Kamada in the 4th quarter worth $67,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of Kamada in the third quarter valued at about $77,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.